FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367397410> ?p ?o ?g. }

• W4367397410 endingPage "106976" @default.
• W4367397410 startingPage "106976" @default.
• W4367397410 abstract "Immunotherapy and FGFR3-targeted therapy play an important role in the management of locally advanced and metastatic bladder cancer (BLCA). Previous studies indicated that FGFR3 mutation (mFGFR3) may be involved in the alterations of immune infiltration, which may affect the priority or combination of these two treatment regimes. However, the specific impact of mFGFR3 on the immunity and how FGFR3 regulates the immune response in BLCA to affect prognosis remain unclear. In this study, we aimed to elucidate the immune landscape associated with mFGFR3 status in BLCA, screen immune-related gene signatures with prognostic value, and construct and validate a prognostic model. ESTIMATE and TIMER were used to assess the immune infiltration within tumors in the TCGA BLCA cohort based on transcriptome data. Further, the mFGFR3 status and mRNA expression profiles were analyzed to identify immune-related genes that were differentially expressed between patients with BLCA with wild-type FGFR3 or mFGFR3 in the TCGA training cohort. An FGFR3-related immune prognostic score (FIPS) model was established in the TCGA training cohort. Furthermore, we validated the prognostic value of FIPS with microarray data in the GEO database and tissue microarray from our center. Multiple fluorescence immunohistochemical analysis was performed to confirm the relationship between FIPS and immune infiltration. mFGFR3 resulted in differential immunity in BLCA. In total, 359 immune-related biological processes were enriched in the wild-type FGFR3 group, whereas none were enriched in the mFGFR3 group. FIPS could effectively distinguish high-risk patients with poor prognosis from low-risk patients. The high-risk group was characterized by a higher abundance of neutrophils; macrophages; and follicular helper, CD4, and CD8 T-cells than the low-risk group. In addition, the high-risk group exhibited higher expression of PD-L1, PD-1, CTLA-4, LAG-3, and TIM-3 than the low-risk group, indicating an immune-infiltrated but functionally suppressed immune microenvironment. Furthermore, patients in the high-risk group exhibited a lower mutation rate of FGFR3 than those in the low-risk group. FIPS effectively predicted survival in BLCA. Patients with different FIPS exhibited diverse immune infiltration and mFGFR3 status. FIPS might be a promising tool for selecting targeted therapy and immunotherapy for patients with BLCA." @default.
• W4367397410 created "2023-04-30" @default.
• W4367397410 creator A5001746337 @default.
• W4367397410 creator A5029502087 @default.
• W4367397410 creator A5033775448 @default.
• W4367397410 creator A5042241049 @default.
• W4367397410 creator A5042464922 @default.
• W4367397410 creator A5053347862 @default.
• W4367397410 creator A5069139703 @default.
• W4367397410 creator A5084926383 @default.
• W4367397410 date "2023-08-01" @default.
• W4367397410 modified "2023-10-14" @default.
• W4367397410 title "FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer" @default.
• W4367397410 cites W1971208896 @default.
• W4367397410 cites W2004630197 @default.
• W4367397410 cites W2016732129 @default.
• W4367397410 cites W2022188526 @default.
• W4367397410 cites W2036215348 @default.
• W4367397410 cites W2058579473 @default.
• W4367397410 cites W2124427232 @default.
• W4367397410 cites W2130430382 @default.
• W4367397410 cites W2133650808 @default.
• W4367397410 cites W2141298701 @default.
• W4367397410 cites W2141454853 @default.
• W4367397410 cites W2142902504 @default.
• W4367397410 cites W2144747113 @default.
• W4367397410 cites W2158497151 @default.
• W4367397410 cites W2160129064 @default.
• W4367397410 cites W2262857054 @default.
• W4367397410 cites W2289712604 @default.
• W4367397410 cites W2341235120 @default.
• W4367397410 cites W2398131194 @default.
• W4367397410 cites W2588916311 @default.
• W4367397410 cites W2595713273 @default.
• W4367397410 cites W2596919342 @default.
• W4367397410 cites W2763670669 @default.
• W4367397410 cites W2765224588 @default.
• W4367397410 cites W2774663121 @default.
• W4367397410 cites W2781097747 @default.
• W4367397410 cites W2794165001 @default.
• W4367397410 cites W2883464812 @default.
• W4367397410 cites W2889646458 @default.
• W4367397410 cites W2899145148 @default.
• W4367397410 cites W2907123184 @default.
• W4367397410 cites W2914335731 @default.
• W4367397410 cites W2945198114 @default.
• W4367397410 cites W2954656275 @default.
• W4367397410 cites W2964014383 @default.
• W4367397410 cites W2970704945 @default.
• W4367397410 cites W2980588864 @default.
• W4367397410 cites W2980870427 @default.
• W4367397410 cites W3004126876 @default.
• W4367397410 cites W3105033030 @default.
• W4367397410 cites W4213157778 @default.
• W4367397410 cites W4283574370 @default.
• W4367397410 cites W4291301630 @default.
• W4367397410 doi "https://doi.org/10.1016/j.compbiomed.2023.106976" @default.
• W4367397410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37301098" @default.
• W4367397410 hasPublicationYear "2023" @default.
• W4367397410 type Work @default.
• W4367397410 citedByCount "0" @default.
• W4367397410 crossrefType "journal-article" @default.
• W4367397410 hasAuthorship W4367397410A5001746337 @default.
• W4367397410 hasAuthorship W4367397410A5029502087 @default.
• W4367397410 hasAuthorship W4367397410A5033775448 @default.
• W4367397410 hasAuthorship W4367397410A5042241049 @default.
• W4367397410 hasAuthorship W4367397410A5042464922 @default.
• W4367397410 hasAuthorship W4367397410A5053347862 @default.
• W4367397410 hasAuthorship W4367397410A5069139703 @default.
• W4367397410 hasAuthorship W4367397410A5084926383 @default.
• W4367397410 hasConcept C121608353 @default.
• W4367397410 hasConcept C126322002 @default.
• W4367397410 hasConcept C143998085 @default.
• W4367397410 hasConcept C203014093 @default.
• W4367397410 hasConcept C2777701055 @default.
• W4367397410 hasConcept C2780352672 @default.
• W4367397410 hasConcept C502942594 @default.
• W4367397410 hasConcept C71924100 @default.
• W4367397410 hasConcept C72563966 @default.
• W4367397410 hasConcept C86803240 @default.
• W4367397410 hasConcept C8891405 @default.
• W4367397410 hasConceptScore W4367397410C121608353 @default.
• W4367397410 hasConceptScore W4367397410C126322002 @default.
• W4367397410 hasConceptScore W4367397410C143998085 @default.
• W4367397410 hasConceptScore W4367397410C203014093 @default.
• W4367397410 hasConceptScore W4367397410C2777701055 @default.
• W4367397410 hasConceptScore W4367397410C2780352672 @default.
• W4367397410 hasConceptScore W4367397410C502942594 @default.
• W4367397410 hasConceptScore W4367397410C71924100 @default.
• W4367397410 hasConceptScore W4367397410C72563966 @default.
• W4367397410 hasConceptScore W4367397410C86803240 @default.
• W4367397410 hasConceptScore W4367397410C8891405 @default.
• W4367397410 hasLocation W43673974101 @default.
• W4367397410 hasLocation W43673974102 @default.
• W4367397410 hasOpenAccess W4367397410 @default.
• W4367397410 hasPrimaryLocation W43673974101 @default.
• W4367397410 hasRelatedWork W1979321249 @default.
• W4367397410 hasRelatedWork W1996150995 @default.

• next